Suchergebnisse

CRISPR Therapeutics AG (CRSP) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2025. This widely-known consensus

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's

In the latest close session, CRISPR Therapeutics AG (CRSP) was up +2.7% at $51.31. This move outpaced the S&P 500's daily gain of 0.54%. Elsewhere, the Dow saw an upswing of 1.05%, while the

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $54.65, marking a -1.57% move from the previous day. This move lagged the S&P 500's daily gain of 0.5%. On the other hand, the

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.37 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to a loss of $0.44 per share a year ago. These